In GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.
Teva Pharmaceutical Industries posted a slightly smaller than expected drop in first-quarter 2019 profit and forecast a sharp rise in 2020 revenue from the company’s new migraine drug Ajovy.
Merck & Co. filed with the U.S. Securities and Exchange Commission that the company plans an extensive restructuring of its manufacturing and supply network.
Merck & Co. reported higher-than-expected Q1 profit on increased demand for vaccines and the cancer immunotherapy Keytruda, and raised the company’s 2019 earnings and revenue forecasts.
Pfizer beat Wall Street estimates for Q1 profit and slightly raised the company’s 2019 earnings forecast as the largest U.S. drugmaker reined in costs and recorded higher Ibrance and Prevnar sales.
Eli Lilly reported lower-than-expected first-quarter 2019 sales for the company’s top-selling diabetes drug Trulicity, due in part to patient affordability programs.
Novartis raised the company’s 2019 profit target, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval in May 2019.
Fresenius Kabi is investing $100 million in expanding the German company’s manufacturing campus in Wilson County, North Carolina, which will add at least 445 new jobs.
W2O – an innovative, analytics-driven, digital-first marketing and communications firm – reported a 23 percent increase in revenue to $177 million in 2018 from $144 million in 2017.
Juno Therapeutics Inc.’s second-quarter loss widened as the biopharmaceutical company logged higher expenses as it ramps up operations following its December initial public offering. Research-and-development expenses surged to $60.2 […]
